...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Circulation journal >Cost-Effectiveness of Percutaneous Coronary Intervention Compared With Medical Therapy for Ischemic Heart Disease in Japan
【24h】

Cost-Effectiveness of Percutaneous Coronary Intervention Compared With Medical Therapy for Ischemic Heart Disease in Japan

机译：日本经皮冠状动脉介入治疗与药物治疗的成本-效果比较

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The cost-effectiveness of percutaneous coronary intervention (PCI) for ischemic heart disease is undetermined in Japan. The aim of this study was to analyze the cost-effectiveness of PCI compared with medical therapy for ST-elevation myocardial infarction (STEMI) and angina pectoris (AP) in Japan. Methods?and?Results: We used Markov models for STEMI and AP to assess the costs and benefits associated with PCI or medical therapy from a health system perspective. We estimated the incremental cost-effectiveness ratio (ICER), expressed as quality-adjusted life-years (QALY), and ICER Conclusions: In STEMI patients, PCI was cost-effective compared with medical therapy. In AP patients, FFR-guided PCI for symptomatic patients could be cost-effective compared with medical therapy. FFR-guided PCI for asymptomatic patients with myocardial ischemia was not cost-effective.
机译：背景：在日本，对于缺血性心脏病的经皮冠状动脉介入治疗（PCI）的成本效益尚未确定。这项研究的目的是分析与日本ST抬高型心肌梗死（STEMI）和心绞痛（AP）的药物治疗相比，PCI的成本效益。方法和结果：我们使用Markov模型用于STEMI和AP从卫生系统的角度评估与PCI或药物治疗相关的成本和收益。我们估计了增量成本效益比（ICER），表示为质量调整生命年（QALY），而ICER结论：在STEMI患者中，PCI与药物治疗相比具有成本效益。在AP患者中，有症状患者的FFR引导PCI与药物治疗相比可能更具成本效益。 FFR引导的无症状心肌缺血患者行PCI并不划算。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号